USA: A new study has found that survival models using electronic health record (EHR) data can accurately predict the ...

Diabetic retinopathy is a common complication of diabetes, which manifests as a potentially severe eye disease that can lead ...

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...

Doctors in India are constantly raising alarms over the rise in cases of vision loss among those battling type 2 ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Breye Therapeutics has announced that danegaptide, a potential oral treatment for nonproliferative diabetic retinopathy, has ...

Robert Wong, MD: Diabetic retinopathy is a small-vessel ischemic disease. When the blood sugars are elevated, it can affect the blood vessels anywhere in your body. It can affect your heart, your ...

Survival models using electronic health record data show promise in predicting progression to proliferative diabetic ...

Diabetic retinopathy can cause blurred vision, blind spots, floaters, poor night vision, and colors that appear faded. It usually affects both eyes.

Diabetic retinopathy is the leading cause of blindness among working-age adults in the United States and affects close to 8 million people.